Compare Novo Nordisk A/S (NVO) vs Oracle Corporation (ORCL) Price & Performance

Novo Nordisk A/STrade

Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Oracle Corporation — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Oracle Corporation trades at $127.6 (market cap $349.63B). The key difference: Oracle Corporation is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.

	NVO	ORCL
Market Cap	$220.53B	$349.63B
Sector	Health	Technology
52-Week High	$71.70	$328.33
52-Week Low	$35.29	$121.37
Enterprise Value	$239.49B	$478.88B
Dividend Yield	3.63%	1.65%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

No Aura AI signal available yet.

Oracle Corporation

Oracle (ORCL) trades at $126.48, up 1.78% today, with a strong fundamental backdrop including revenue growth to $57.40B in 2025 and a net income margin of 25.37%. Recent quarters have consistently beaten EPS estimates, and analyst consensus is bullish with a $253.30 price target. Technicals show a bearish overall signal but with bullish oscillators, and the stock faces support near $125.

The outlook is positive given Oracle's AI infrastructure expansion and earnings momentum, but risks include high debt levels and competitive pressures. The stock offers growth potential if execution continues, yet investors should weigh valuation multiples against sector peers.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 11 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 14 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

ORCL

Oracle shares hit key support and show oversold signs, hinting at a possible rebound soon.FXEmpire · 5 hours agoBullish Big tech's hidden debt hits $1.65T, raising investor risk amid AI investment surge.Finbold · 16 hours agoBearish Oracle shifts to AI hyperscale, faces credit downgrade but shows strong growth potential.Stuart Mooney · 1 day agoNeutral View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.